Nyxoah marked its recent milestones by ringing the Nasdaq Closing Bell, symbolizing the company’s forward momentum as it approaches the potential US market launch of its Genio device for OSA. Summary: Nyxoah SA rang the Nasdaq Closing Bell on Aug 29 to celebrate its … [Read more...]
Nyxoah Appoints New Exec to Lead Expected US Launch of Genio
Summary: Nyxoah SA has appointed Scott Holstine as chief commercial officer to lead the expected US launch of the Genio neurostimulator for obstructive sleep apnea (OSA). The Genio system, which has already received the CE Mark in Europe, is expected to receive FDA approval by … [Read more...]
Genio OSA: Nyxoah Submits Final PMA Application to FDA
Summary: Nyxoah has submitted the fourth and final module of its Premarket Approval (PMA) application to the FDA for its Genio neurostimulator, designed to treat obstructive sleep apnea (OSA). The Genio system, which is fully-body MRI-compatible and powered by a wearable, … [Read more...]
Nyxoah Prepares Final FDA Module for Genio OSA Neurostimulator
Summary: Nyxoah described its Q1 2024 economic and operating outcomes, highlighting sizeable progress with its Genio program, a leadless and battery-cost-free hypoglossal neurostimulation therapy for obstructive snooze apnea (OSA). The Aspiration US pivotal study reached co-key … [Read more...]
Nyxoah Appoints Hypoglossal Nerve Stimulation Pioneer as CMO
Summary: Nyxoah SA has appointed Maurits S. Boon, MD, who is acknowledged for his get the job done in hypoglossal nerve stimulation remedy to deal with obstructive snooze apnea, as chief clinical officer. Boon, from Thomas Jefferson University, contributed to Nyxoah’s Desire US … [Read more...]
Nyxoah, AAO-HNSF to Enhance Access to Sleep Apnea Therapies
Nyxoah SA, maker of the CE-marked Genio neurostimulator for obstructive rest apnea (OSA), signed a strategic partnership to come to be a corporate winner at the Business Circle stage with the American Association of Otolaryngology – Head & Neck Surgery Basis (AAO-HNSF). Nyxoah … [Read more...]
Nyxoah Prepares to Unveil OSA Neurostimulation Study Results
Nyxoah SA announced the upcoming release of efficacy and safety data from the DREAM US pivotal study on the Genio neurostimulation system for obstructive sleep apnea (OSA). The results are expected by early April, according to the company’s fourth-quarter and full-year 2023 … [Read more...]